Overview The Effect of QVA149 on Patient Reported Dyspnea in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Status: Completed Trial end date: 2012-08-01 Target enrollment: Participant gender: Summary This study assessed the effect of QVA149 on patient-reported dyspnea in moderate to severe Chronic Obstructive Pulmonary Disease (COPD) patients. Phase: Phase 3 Details Lead Sponsor: Novartis PharmaceuticalsTreatments: AlbuterolGlycopyrrolateTiotropium Bromide